| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, May 9 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex:
CXM) today reported recent highlights and developments, as well as
financial results for its first quarter ended March 31, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
Highlights and Recent Developments
-- European commercialization agreement with Euromed Medizinisch GmbH
(Euromed) for InnerCool's CoolBlue(TM) surface temperature modulation
system and RapidBlue endovascular system. Euromed, a leading
distributor of cardiology medical products will have exclusive
marketing, sales and distribution rights in Austria, Germany and
Switzerland for InnerCool's portfolio of temperature modulation
systems.
-- Australian distribution agreement with Lifehealthcare Pty Ltd., one of
Australia's leading medical device distributors and health service
providers. Under the agreement, Lifehealthcare has the exclusive
rights to market, sell and distribute InnerCool's CoolBlue and
RapidBlue temperature modulation systems in Australia and New Zealand.
-- Publication by BioMed Central (BMC) Cardiovascular Disorders
(2008, 8:7, April 10, 2008) of positive findings from a preclinical
study conducted by researchers at Lund University Hospital in Sweden
demonstrating a new and expanded benefit of early rapid cooling for the
potential treatment of acute myocardial infarction (heart attack). The
same researchers are currently recruiting patients for the RAPID-MI-ICE
(Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to
Percutaneous Coronary Intervention) clinical study, which is expected
to enroll approximately 20 patients who present within six hours of
their hea
'/>"/>
| SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |